Published on 22 Jul 2022 on Zacks via Yahoo Finance

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

Article preview image

This week, J&J JNJ set in motion the second-quarter earnings season for the drug and biotech sector with an earnings and sales beat. Novartis NVS reported mixed results. GSK plc GSK completed the separation of its Consumer Healthcare (CHC) segment into a new company, Haleon. Merck’s (MRK) head and neck cancer study on Keytruda failed while AbbVie ABBV filed a regulatory application in Europe seeking approval for its migraine candidate atogepant.

Recap of the Week’s Most Important Stories

J&J Beats on Q2 Earnings & Sales, Lowers View: J&J reported better-than-expected second-quarter results as it beat estimates for both earnings and sales. Its Pharmaceuticals unit continued to do well. Its COVID-19 vaccine sales improved in the second quarter after a lower-than-expected contribution in the first quarter. Sales in the MedTech segment continued to improve. However, sales were partly hurt by COVID-related restrictions in countries like China and labor and supply constraints.

NASDAQ.SNY price evolution
NYSE.NVS price evolution
PAR.SAN price evolution
LSE.AZN price evolution
SIX.NOVN price evolution
PAR.MRK price evolution
LSE.APH price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Novartis (VTX:NOVN) Is Paying Out A Larger Dividend Than Last Year

Novartis AG's (VTX:NOVN) dividend will be increasing from last year's payment of the same period ...

Simply Wall St. via Yahoo Finance 4 Feb 2023

Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off

Novartis AG (NYSE: NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating t...

Benzinga via Yahoo Finance 1 Feb 2023

Novartis Stock Down On Weak Q4 Results; Sees Growth In FY23

Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland af...

RTT News 1 Feb 2023

Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates

Novartis AG NVS reported mixed fourth-quarter results for 2022. Core earnings (excluding one-time...

Zacks via Yahoo Finance 1 Feb 2023

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Incyte Corporation INCY is scheduled to release its fourth-quarter and full-year 2022 results on ...

Zacks via Yahoo Finance 31 Jan 2023

11 Most Undervalued Blue Chip Stocks To Buy According To Hedge Funds

In this article, we will take a look at the top 11 most undervalued blue chip stocks to buy accor...

Insider Monkey via Yahoo Finance 31 Jan 2023

15 Biggest Neuroscience Companies in the World

In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip...

Insider Monkey via Yahoo Finance 30 Jan 2023

Swiss Helvetia Fund: Pricey; Unattractive Risk-Reward (NYSE:SWZ)

The Swiss Helvetia Fund (NYSE:SWZ), a closed-end fund managed by Schroders (OTCPK:SHNWF) offering...

Seeking Alpha 27 Jan 2023

Eaton Vance Worldwide Health S -

GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Health care-focused ...

Guru Focus 27 Jan 2023

3 Stocks It Is Time to Buy Now

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain...

Entrpreneur 27 Jan 2023